NYSE:CAVA

Cava Group (NYSE: CAVA) Q1 Earnings Beat, Revenue Jumps

Font: Financial Modeling Prep  • May 20, 2026

Market Chart

Cava Group (NYSE: CAVA) Q1 Earnings Beat Expectations, Fueled by Revenue Growth and Expansion

  • Cava Group (NYSE: CAVA) exceeded Q1 earnings estimates, reporting $0.20 per share.
  • The Mediterranean fast-casual chain saw robust revenue growth of 32.2% to $434.4 million, supported by strong same-restaurant sales and customer traffic.
  • Cava Group continues its strategic expansion, opening 20 net new restaurants, though its valuation metrics like a P/E ratio of 142.25 reflect high growth expectations.

Cava Group (NYSE: CAVA) is a leading fast-casual restaurant chain that specializes in Mediterranean food. The company is actively expanding its market presence, recently opening new locations in the Midwest. As highlighted by Business Wire, Co-Founder and CEO Brett Schulman states that Cava Group solidifies its leading position in its category despite economic uncertainty.

For its first quarter, Cava Group reports earnings of $0.20 per share. This figure surpasses the Zacks Consensus Estimate of $0.17, as highlighted by Zacks. However, this result is a slight decrease from the earnings of $0.22 per share from the same quarter of the previous year.

The company posts revenues of $434.4 million, a 32.2% increase. This revenue growth is supported by a 9.7% rise in same-restaurant sales. A key driver for this sales increase is a 6.8% growth in customer traffic, showing more people are dining at its locations.

Cava Group's expansion strategy includes opening 20 net new restaurants, bringing its total to 459 locations. The company's stock valuation reflects investor expectations for future growth, with a high price-to-earnings (P/E) ratio of 142.25. A P/E ratio compares a company's stock price to its earnings per share.

Other valuation metrics for Cava Group include a price-to-sales (P/S) ratio of 7.71. The company's enterprise value-to-sales (EV/Sales) ratio is 7.46, while its enterprise value-to-operating cash flow (EV/OCF) ratio is 47.61. These financial ratios help investors assess the company's value against its sales and cash generation.

Market Overview
LIMN
Liminatus Pharma, Inc. Class A Common Stock
$0.28
48.56%
SBFM
Sunshine Biopharma, Inc.
$0.51
38.06%
SOXS
Direxion Daily Semiconductor Bear 3X ETF
$8.54
0.00%
TZA
Direxion Daily Small Cap Bear 3X ETF
$4.82
-0.21%
NVDA
NVIDIA Corporation
$220.19
-1.47%
WOK
WORK Medical Technology Group Ltd.
$0.15
-22.65%
CXAI
CXApp Inc.
$0.22
21.97%
RGTI
Rigetti Computing, Inc.
$21.16
25.33%
NIVF
NewGenIvf Group Limited
$1.14
54.26%
NCPL
Netcapital Inc.
$0.68
48.84%